Jabre Capital Partners’s Sarepta Therapeutics SRPT Stock Holding History

Jabre Capital Partners’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-2,300	Closed	-$371K	–	88
2018 Q3	$371K	Hold	2,300	–	–	0.12%	100
2018 Q2	$304K	Sell	2,300 -3,600	-61%	-$339K	0.02%	153
2018 Q1	$437K	Buy	+5,900	New	+$393K	0.09%	124
2017 Q3	–	Sell	-13,000	Closed	-$438K	–	124
2017 Q2	$438K	Sell	13,000 -2,000	-13%	-$65.1K	0.04%	101
2017 Q1	$444K	Buy	+15,000	New	+$464K	0.05%	105

Other funds holding SRPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Jabre Capital Partners's SRPT Position: Q4 2018 in Review

Jabre Capital Partners sold out of Sarepta Therapeutics (SRPT) in Q4 2018, closing a stake of 2,300 shares — an estimated $371K sold.

Jabre Capital Partners first reported a position in SRPT in Q1 2017 and held it in 5 quarters. The position peaked at $444K in Q1 2017. 335 funds tracked by Wall St. Rank hold SRPT as of Q4 2018.

Jabre Capital Partners reported no remaining Sarepta Therapeutics position as of Q4 2018 after selling out during the quarter.
Jabre Capital Partners sold 2,300 Sarepta Therapeutics shares in Q4 2018, an estimated $371K.
Jabre Capital Partners first reported a position in Sarepta Therapeutics in Q1 2017 and held it in 5 quarters.
Jabre Capital Partners's Sarepta Therapeutics position peaked at $444K in Q1 2017.
335 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2018.

Based on Jabre Capital Partners's 13F filing for Q4 2018, filed 14 Feb 2019.